"The US Food and Drug Administration (FDA) has approved soluble ferric pyrophosphate (Triferic, Rockwell Medical) to replace iron and maintain hemoglobin in adults with chronic kidney disease who are undergoing dialysis.
The electrolyte solution contained in compartment A must be mixed with the buffer solution of compartment B before use in order to obtain the reconstituted solution suitable for hemofiltration / hemodiafiltration.
Do not administer the reconstituted solution unless it is clear and free of visible particulate matter.
PrismaSol solution (sterile hemofiltration hemodiafiltration solution) includes several formulations. Selection of a specific formulation depends on the patient's condition and treatment procedures.
Administration of the solution should only be under the direction of a physician competent in intensive care treatment including CRRT.
The patient's hemodynamic fluid, electrolyte and acid-base balance should be monitored throughout the procedure. Note that citrate, when used as an anticoagulant, contributes to the base load and can reduce plasma calcium levels.
During hemofitration, hemodiafiltration, or hemodialysis, abnormalities in the plasma concentration of potassium, calcium, and glucose may develop. These abnormalities may be corrected by the use of appropriate formulations of PrismaSol. Abnormalities in plasma phosphate concentration, especially hypophosphatemia, may also occur. Hypophosphatemia may require phosphate supplementation to maintain plasma concentrations in the physiologic range.
Use only with continuous extra-corporeal blood purification equipment in CRRT.
Incorrect use of the access ports or other restrictions to fluid flow wil result in machine alarms. Ignoring and/or overriding repetitive alarms without resolving the originating cause might lead to incorrect patient weight loss and result in patient injury or death.
The solution may be heated to no more than 40°C/l04° F and this must be carefully controlled. After heating, verify that the solution remains clear and contains no particulate matter.
Diabetes Melltus or Glucose Intolerance
Patients may require initiation of insulin therapy or modification of insulin dosage during treatment with PrismaSol solution (sterile hemofiltration hemodiafiltration solution) . Appropriate monitoring of blood glucose should be performed and insulin dosage adjusted accordingly.
Last reviewed on RxList: 12/29/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional PrismaSol Solution Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.